Mayo Clinic patented a method using senolytic agents like dasatinib to improve arteriovenous fistula (AVF) maturation for hemodialysis. The method aims to enhance AVF functionality and maintain patency, potentially improving outcomes for patients requiring vascular access. GlobalData’s report on Mayo Clinic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Mayo Clinic, was a key innovation area identified from patents. Mayo Clinic's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Improving arteriovenous fistula maturation and functionality using senolytic agents
A recently granted patent (Publication Number: US11925640B2) discloses a method for promoting arteriovenous fistula maturation in mammals, particularly humans, by administering a composition containing dasatinib, tocotrienol, quercetin, or a combination of these components. This method aims to facilitate the development of an effective vascular access point for hemodialysis by promoting the maturation of arteriovenous fistulas.
Furthermore, the patent also covers methods for maintaining the functionality and patency of arteriovenous fistulas in mammals, including humans, through the administration of compositions containing dasatinib, tocotrienol, quercetin, or a combination thereof. By locally administering these compositions to the arteriovenous fistula, the method aims to ensure that the fistula remains functional and open, serving as an effective vascular access point for hemodialysis. These methods offer potential advancements in the field of vascular access management for hemodialysis patients, providing new avenues for improving the outcomes and quality of care in this critical medical area.
To know more about GlobalData’s detailed insights on Mayo Clinic, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.